Insider · CIK 0001619834
Steven Keith Burke
Files at SCYX (SCYNEXIS INC), AKBA (Akebia Therapeutics, Inc.). First filing Feb 4, 2025, latest Mar 4, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKBA: Akebia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 3Weak | Akebia Therapeutics, Inc. | $13k 7,144 shares | -1% | - | |
| 20Weak | Akebia Therapeutics, Inc. | $106k 50,506 shares | -6% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | SCYX SCYNEXIS INC | AGrant or award Common Stock | +5,750 | $0.00 | $0 | 5,750 | 20 d ago |
| Sep 18, 2026 | SCYX SCYNEXIS INC | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | 20 d ago |
| Mar 3, 2025 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -7,144 | $1.83 | $13k | 809,090 | Mar 4, 2025 |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | AGrant or award Common Stock10b5-1 | +194,900 | $0.00 | $0 | 866,740 | Feb 4, 2025 |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -23,270 | $2.10 | $49k | 843,470 | Feb 4, 2025 |
| Feb 3, 2025 | AKBA Akebia Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -27,236 | $2.10 | $57k | 816,234 | Feb 4, 2025 |
| Jan 31, 2025 | AKBA Akebia Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative10b5-1 | +292,300 | $0.00 | $0 | 292,300 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.